Damora Therapeutics (DMRA) Income from Continuing Operations (2019 - 2026)
Damora Therapeutics posted quarterly Income from Continuing Operations of 27783000.0 for Q1 2026, down 996.84% year-on-year from 3097871.15 in Q1 2025, and up 85.89% on a QoQ basis from 196876000.0 in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of Income from Continuing Operations data on file, last reported at 27783000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 996.84% year-over-year to 27783000.0; the trailing twelve-month figure through Mar 2026 stood at 231229000.0 (down 3133.97% YoY), and the FY2025 full-year result was 205979000.0, down 1940.61% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 27783000.0, up from 196876000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4604000.0 in Q4 2024 and bottomed at 196876000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 8136000.0 (2023), against an average of 20230000.0.
- The widest annual swing landed in 2024, when Income from Continuing Operations soared 171.1%; it then plunged 4376.19% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 13525000.0 in 2022, then soared by 52.13% to 6475000.0 in 2023, then jumped by 171.1% to 4604000.0 in 2024, then slumped by 4376.19% to 196876000.0 in 2025, then jumped by 85.89% to 27783000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 27783000.0 (Q1 2026), 196876000.0 (Q4 2025), and 3133000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | -27.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.78 Mn |
| Dec 31, 2025 | -196.88 Mn |
| Sep 30, 2025 | -3.13 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Mar 31, 2025 | -2.53 Mn |
| Dec 31, 2024 | 4.60 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Jun 30, 2024 | -5.34 Mn |
| Mar 31, 2024 | -5.48 Mn |
| Dec 31, 2023 | -6.48 Mn |
| Sep 30, 2023 | -8.14 Mn |
| Jun 30, 2023 | -10.74 Mn |
| Mar 31, 2023 | -13.49 Mn |
| Dec 31, 2022 | -13.53 Mn |
| Sep 30, 2022 | -13.62 Mn |
| Jun 30, 2022 | -17.12 Mn |
| Mar 31, 2022 | -16.94 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -12.94 Mn |
| Jun 30, 2021 | -12.27 Mn |
| Mar 31, 2021 | -13.55 Mn |
| Dec 31, 2020 | -11.30 Mn |
| Sep 30, 2020 | -10.17 Mn |
| Jun 30, 2020 | -6.34 Mn |
| Mar 31, 2020 | -5.83 Mn |
| Dec 31, 2019 | 24.85 Mn |
| Sep 30, 2019 | 4.83 Mn |